UA117448C2 - Середовище клітинної культури для культивування ооцита - Google Patents
Середовище клітинної культури для культивування ооцитаInfo
- Publication number
- UA117448C2 UA117448C2 UAA201400826A UAA201400826A UA117448C2 UA 117448 C2 UA117448 C2 UA 117448C2 UA A201400826 A UAA201400826 A UA A201400826A UA A201400826 A UAA201400826 A UA A201400826A UA 117448 C2 UA117448 C2 UA 117448C2
- Authority
- UA
- Ukraine
- Prior art keywords
- osc
- oocyte
- inhibitor
- stem cell
- nad
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Abstract
Винахід стосується середовища клітинної культури для культивування ооцита, стовбурової клітини оогоніїв (OSC), потомка OSC або передімплантаційної зіготи, де зазначена OSC, одержана з оваріальної тканини, являє собою виділену стовбурову клітину, що не є ембріональною та є мітотично компетентною і експресує Vasa, Oct-4, Dazl i Stella, де зазначене середовище клітинної культури містить інгібітор CD38 та попередник нікотинамідаденіндинуклеотиду (NAD), де зазначений інгібітор CD38 являє собою сполуку, вибрану з групи, що складається з апігеніну, лютеоліну, тирфостину-8, берберину і SRT-1720, та де зазначені інгібітор CD38 і попередник NAD присутні у зазначеному середовищі у кількості, ефективній для покращення біоенергетичного стану зазначених ооцита, OSC, потомка OSC або передімплантаційної зиготи, культивованих у зазначеному середовищі. Винахід також стосується композиції, що містить виділений ооцит, стовбурову клітину оогоніїв (OSC), потомок OSC або препарат мітохондрій, та зазначені інгібітор CD38 і попередник NAD; способу культивування ооцита та способу одержання ооцита для застосування у заплідненні in vitro.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502840P | 2011-06-29 | 2011-06-29 | |
US201261600529P | 2012-02-17 | 2012-02-17 | |
PCT/US2012/033672 WO2013002880A1 (en) | 2011-06-29 | 2012-04-13 | Compositions and methods for enhancing bioenergetic status in female germ cells |
Publications (1)
Publication Number | Publication Date |
---|---|
UA117448C2 true UA117448C2 (uk) | 2018-08-10 |
Family
ID=47424472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201400826A UA117448C2 (uk) | 2011-06-29 | 2012-04-13 | Середовище клітинної культури для культивування ооцита |
Country Status (13)
Country | Link |
---|---|
US (4) | US9845482B2 (uk) |
EP (2) | EP3495470A1 (uk) |
JP (3) | JP6284475B2 (uk) |
CN (1) | CN103827293A (uk) |
AU (2) | AU2012276038B2 (uk) |
BR (1) | BR112013033797A2 (uk) |
CA (1) | CA2847292A1 (uk) |
EA (1) | EA201490050A1 (uk) |
IL (2) | IL230212B (uk) |
MX (1) | MX356815B (uk) |
UA (1) | UA117448C2 (uk) |
WO (1) | WO2013002880A1 (uk) |
ZA (1) | ZA201309707B (uk) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
US8647869B2 (en) * | 2011-04-14 | 2014-02-11 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
EP2741757B1 (en) * | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
WO2013171752A1 (en) | 2012-05-16 | 2013-11-21 | Minovia Therapeutics Ltd. | Compositions and methods for inducing angiogenesis |
EP4233878A1 (en) | 2013-03-15 | 2023-08-30 | Washington University | Administration of nicotinamide mononucleotide in the treatment of dry eye |
CA2934579A1 (en) * | 2013-12-20 | 2015-06-25 | Fertilify Inc. | Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health |
CN104188966B (zh) * | 2014-07-14 | 2017-12-12 | 吴效科 | 小檗碱在制备治疗排卵障碍性不孕症的药物中的应用 |
US10323058B2 (en) | 2014-07-24 | 2019-06-18 | W. R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
CN104164401A (zh) * | 2014-08-12 | 2014-11-26 | 沈阳洁瑞生物技术有限公司 | 精子洗涤液及其制备方法 |
EP2995948A1 (en) * | 2014-09-09 | 2016-03-16 | Ecole Polytechnique Federale de Lausanne (EPFL) | Methods and compounds useful in hematopoietic stem cell medicine |
BR112017003263A2 (pt) * | 2014-09-16 | 2017-11-28 | Ovascience Inc | anticorpos anti-vasa, e métodos de produção e utilização dos mesmos |
EP3237008A1 (en) * | 2014-12-24 | 2017-11-01 | Pierre Fabre Medicament | Novel humanized adam17 antibody |
EP3261649A4 (en) | 2015-02-26 | 2018-08-15 | Minovia Therapeutics Ltd. | Mammalian cells enriched with functional mitochondria |
EP3268379B1 (en) | 2015-03-09 | 2023-11-01 | W.R. Grace & CO. - CONN. | Crystalline form of nicotinamide riboside |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
CN106244548B (zh) * | 2015-06-09 | 2019-07-05 | 成都中医药大学 | 木犀草素在诱导间充质干细胞向神经细胞定向分化中的用途 |
WO2016210232A1 (en) * | 2015-06-25 | 2016-12-29 | N.V. Perricone Llc | Niacinamide mononucleotide formulations for skin aging |
WO2017079428A1 (en) * | 2015-11-04 | 2017-05-11 | President And Fellows Of Harvard College | Site specific germline modification |
PL3484486T3 (pl) | 2016-07-15 | 2023-12-11 | H2 Water Technologies Ltd | Kompozycja do produkcji wody bogatej w wodór |
JP7097542B2 (ja) * | 2016-09-26 | 2022-07-08 | 学校法人 聖マリアンナ医科大学 | 卵巣機能の低下予防又は改善剤 |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
AU2017367092B2 (en) * | 2016-11-29 | 2022-11-03 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
US11634690B2 (en) | 2017-01-31 | 2023-04-25 | Oriental Yeast Co., Ltd. | Agent for accelerating growth of pluripotent stem cells |
RU2662983C1 (ru) * | 2017-01-31 | 2018-07-31 | Алексей Юрьевич Грязнов | Культуральная среда для ооцитов и эмбрионов |
WO2018160920A1 (en) * | 2017-03-02 | 2018-09-07 | Orig3N, Inc. | Systems and methods of assisted reproduction and prevention of genetic defects in offspring using induced pluripotent stem cells |
WO2018200357A1 (en) * | 2017-04-26 | 2018-11-01 | Elysium Health, Inc. | Methods and compositions of improving fertility |
US20200179441A1 (en) * | 2017-04-27 | 2020-06-11 | H2 Water Technologies Ltd. | Synergistic compositions for increasing mitochondrial function and energy |
US11179423B2 (en) * | 2017-05-31 | 2021-11-23 | Palo Alto Investors | Methods of enhancing female fertility |
CN107308200A (zh) * | 2017-06-19 | 2017-11-03 | 北正赛欧(北京)生物科技有限公司 | 用于治疗宫颈癌的组合物及其应用 |
EP3661601A4 (en) * | 2017-07-31 | 2020-10-07 | Newsouth Innovations Pty Limited | PROCESS FOR INCREASING FERTILITY |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
FI3697785T3 (fi) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidatsopyridiiniyhdisteitä pad:n estäjinä |
EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
JP7368369B2 (ja) | 2017-11-24 | 2023-10-24 | ジュビラント・エピスクライブ・エルエルシー | Prmt5阻害剤としてのヘテロ環式化合物 |
CN108384751A (zh) * | 2018-03-12 | 2018-08-10 | 山大生殖研发中心有限公司 | 卵母细胞体外成熟培养方法和培养基 |
JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pd1/pd-l1相互作用/活性化の阻害剤としての二環式化合物 |
CN108642001B (zh) * | 2018-05-08 | 2022-09-02 | 中国农业科学院北京畜牧兽医研究所 | 一种提高牛性控冻精体外受精能力的方法 |
KR20210118356A (ko) * | 2018-05-15 | 2021-09-30 | 점프스타트 퍼틸리티 피티와이 엘티디 | 노화방지제로서의 니코틴산 모노뉴클레오타이드의 무기 염 |
JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
WO2020028684A1 (en) * | 2018-08-01 | 2020-02-06 | Jumpstart Fertility Pty Ltd | Salts of nicotinic acid and nicotinamide as anti-aging agents |
AU2019314476A1 (en) * | 2018-08-01 | 2021-02-25 | Roland Dolle | Quaternary ammonium salts of nicotinic acid and nicotinamide mononucloetides and ribosides as anti-aging agents |
CA3122246A1 (en) * | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Synergistic compositions of bioactive agents for optimizing cellular health |
CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
CN111617093A (zh) * | 2019-06-13 | 2020-09-04 | 中国科学院广州生物医药与健康研究院 | 化合物在制备药物中的用途 |
WO2020257285A1 (en) * | 2019-06-17 | 2020-12-24 | The Brigham And Women's Hospital, Inc. | Materials and methods for generating functional oocytes |
JPWO2020262325A1 (uk) * | 2019-06-28 | 2020-12-30 | ||
WO2021158601A1 (en) * | 2020-02-03 | 2021-08-12 | Blue California | Methods and compositions related to the use of ergothioneine |
WO2021168419A1 (en) * | 2020-02-20 | 2021-08-26 | Northeastern University | Methods and compositions for use of mitochondrial therapies to improve female reproductive potential |
JP7289042B2 (ja) * | 2020-03-04 | 2023-06-09 | パナソニックIpマネジメント株式会社 | 洗濯機 |
TWI753404B (zh) * | 2020-04-16 | 2022-01-21 | 國立屏東科技大學 | 輸卵管幹細胞促進卵母細胞體外成熟和胚發育之製劑、製備方法及其用途 |
CN111500531A (zh) * | 2020-05-15 | 2020-08-07 | 扬州大学 | 一种鸡PGCs在体外长期培养的方法 |
US20210369751A1 (en) * | 2020-06-02 | 2021-12-02 | Mediwel Labs, LLC | Biologically active compositions and methods of using |
KR20230066015A (ko) * | 2020-09-08 | 2023-05-12 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | 정자 운동성 개선제 및 정자 운동성 개선 방법 |
CN111925986B (zh) * | 2020-09-24 | 2021-01-19 | 深圳市一五零生命科技有限公司 | 一种脐带间充质干细胞无血清培养基及其制备方法 |
CN114561342A (zh) * | 2020-11-27 | 2022-05-31 | 童国庆 | Nad信号通路激动剂在体外胚胎培养中的应用 |
WO2022159934A1 (en) * | 2021-01-19 | 2022-07-28 | Gallant Pet, Inc. | Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications |
CN115074388B (zh) * | 2021-06-29 | 2023-04-28 | 北京大学深圳医院 | 母源因子诱导的2c样全能干细胞及其转化应用 |
CN113403264A (zh) * | 2021-07-21 | 2021-09-17 | 中国农业大学 | 一种gv期冷冻卵母细胞解冻后体外成熟培养液及其应用 |
CN113599371A (zh) * | 2021-09-06 | 2021-11-05 | 郑州大学 | 二甲双胍在制备预防胸腺退化和/或促进胸腺组织再生药物中的应用 |
CN113797186A (zh) * | 2021-10-27 | 2021-12-17 | 宁夏医科大学 | 二甲双胍在激活雌性生殖干细胞的应用 |
CN113750242A (zh) * | 2021-10-28 | 2021-12-07 | 复旦大学附属中山医院 | Nmn联合cd38抑制剂在制备预防或治疗阿霉素所致心脏毒性药物中的应用 |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
CN115247146A (zh) * | 2021-12-31 | 2022-10-28 | 温州医科大学 | 一种人类胚胎体外培养基及提高体外培养人类胚胎发育潜能的方法 |
JP2023156553A (ja) * | 2022-04-13 | 2023-10-25 | 克昭 團 | 卵巣機能活性化剤、抗老化剤、医薬品、化粧品および食品または飲料 |
CN114917215B (zh) * | 2022-04-27 | 2024-01-23 | 中国科学院生物物理研究所 | 活性化合物预防或治疗卵巢功能障碍性疾病的用途 |
CN115590017B (zh) * | 2022-11-04 | 2023-09-12 | 中国农业大学 | 一种通过降低线粒体温度提高卵母细胞冷冻效果的方法 |
CN115956506B (zh) * | 2023-02-16 | 2023-11-03 | 云南省农业科学院茶叶研究所 | 一种茶树离体再生组织的构建方法 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR475561A (uk) | 1913-07-25 | |||
US3854470A (en) | 1973-11-23 | 1974-12-17 | L Augspurger | Reproduction processes for cellular bodies |
IT1057895B (it) | 1975-02-17 | 1982-03-30 | Serono Lab | Gonadotropina corionica umana parzialmente desalinizzata per indurre l'ouvulazione |
FR2322860A1 (fr) | 1975-09-05 | 1977-04-01 | Aron Sarl | Procede de preparation de chlorhydrate de dimethylbiguanide |
US4193392A (en) | 1977-09-23 | 1980-03-18 | Barnett Gordon R | Method for removing ova from animals |
US4326505A (en) | 1980-01-07 | 1982-04-27 | Occidental Petroleum Corporation | Surgical procedure for embryo transplants on animals |
US4339434A (en) | 1981-08-17 | 1982-07-13 | Gametrics Limited | Method of increasing the incidence of female offspring |
US4845077A (en) | 1984-04-03 | 1989-07-04 | Serono Laboratories, Inc. | Method of inducing ovulation |
FR2563726B1 (fr) | 1984-05-04 | 1986-10-10 | Robert Cassou | Appareil d'insemination artificielle, notamment des carnivores |
US4642094A (en) | 1984-05-29 | 1987-02-10 | North Jr Walter L | Non-surgical embryo transfer device |
US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
US4725579A (en) | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
FR2580933B1 (fr) | 1985-04-24 | 1987-08-07 | Lenck Lucien | Capacite trans-uterine pour fecondation " in vitro in vivo " |
FR2589879B1 (fr) | 1985-11-08 | 1989-05-12 | Claude Ranoux | Conteneur pour culture anaerobie d'embryons humains |
AT387718B (de) | 1986-04-09 | 1989-03-10 | Fischl Franz H Dr | Katheder zur kuenstlichen befruchtung |
FR2608037A1 (fr) | 1986-12-10 | 1988-06-17 | Lenck Lucien | Methode d'intubation destinee a permettre la transplantation de l'oeuf ou de la matiere embryonnaire, et moyens pour sa mise en oeuvre |
FR2609885B1 (fr) | 1987-01-22 | 1989-04-14 | Cassou Robert | Instrument pour l'insemination artificielle, le transfert d'embryons ou le prelevement de liquides folliculaires chez les mammiferes |
US5538948A (en) | 1987-01-30 | 1996-07-23 | Novo Nordisk A/S | Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone |
US4865589A (en) | 1987-04-22 | 1989-09-12 | Ludwig Simmet | Instrument for the transfer of materials such as sperm and embryos |
FR2614626B1 (fr) | 1987-04-30 | 1989-07-21 | Ranoux Claude | Conteneur pour fecondation des ovocytes et replacement des embryons chez l'homme et l'animal |
US5160312A (en) | 1990-02-09 | 1992-11-03 | W. R. Grace & Co.-Conn. | Cryopreservation process for direct transfer of embryos |
US5147315A (en) | 1990-04-06 | 1992-09-15 | C. R. Bard, Inc. | Access catheter and system for use in the female reproductive system |
US5627066A (en) | 1991-05-14 | 1997-05-06 | Mount Sinai School Of Medicine Of The City University Of New York | Method and apparatus for in vitro fertilization |
JPH06507565A (ja) | 1991-05-14 | 1994-09-01 | マウント シナイ スクール オヴ メディスン オヴ ザ シティー ユニバーシティー オヴ ニューヨーク | 体外受精方法および装置 |
FR2678506B1 (fr) | 1991-07-01 | 2000-03-10 | Claude Ranoux | Procede de fecondation en cycle spontane. |
US5744366A (en) | 1992-05-01 | 1998-04-28 | Trustees Of The University Of Pennsylvania | Mesoscale devices and methods for analysis of motile cells |
US5296375A (en) | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
GB9227123D0 (en) | 1992-12-30 | 1993-02-24 | Applied Research Systems | Method |
US5563059A (en) | 1993-02-23 | 1996-10-08 | Genentech, Inc. | Use of human inhibin and human activin to increase the number of mature primate oocytes |
GB9305984D0 (en) | 1993-03-23 | 1993-05-12 | Royal Free Hosp School Med | Predictive assay |
US5360389A (en) | 1993-05-25 | 1994-11-01 | Chenette Philip E | Methods for endometrial implantation of embryos |
US5541081A (en) | 1994-03-22 | 1996-07-30 | President And Fellows Of Harvard College | Process for assessing oocyte and embryo quality |
GB9410639D0 (en) | 1994-05-27 | 1994-07-13 | Queen Mary & Westfield College | Method of improving fertilization |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
JP3660026B2 (ja) | 1995-09-04 | 2005-06-15 | 扶桑薬品工業株式会社 | 体外受精用培地組成物 |
US5827174A (en) | 1995-09-26 | 1998-10-27 | Reuss, Jr.; William Alexander | Biological speciman containment and incubation pouch |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
US6040340A (en) | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
US5824548A (en) | 1996-05-29 | 1998-10-20 | Wisconsin Alumni Research Foundation | Method of increasing survival of cultured primate embryos in medium containing exogenous gonadotrophin releasor hormone |
EP0954563B1 (en) * | 1996-10-10 | 2008-07-02 | Invitrogen Corporation | Animal cell culture media comprising plant-derived nutrients |
CA2199663C (en) | 1997-03-11 | 2004-08-10 | Ruth Miriam Moses | In vitro maturation and fertilization of mammalian oocytes |
US5935968A (en) | 1997-03-17 | 1999-08-10 | Merck & Co., Inc. | Methods for treating polycystic ovary syndrome |
JP2000516641A (ja) | 1997-07-02 | 2000-12-12 | エスディージー インコーポレイテッド | 診断および治療用途の目標指向性リポソーム構成物 |
US5961444A (en) | 1997-10-17 | 1999-10-05 | Medworks Corporation | In vitro fertilization procedure using direct vision |
US6010448A (en) | 1997-10-17 | 2000-01-04 | Medworks Corp | Embryo transfer arrangement |
US6196965B1 (en) | 1998-05-21 | 2001-03-06 | Cryofacets, Inc. | Compositions methods and devices for embryo implantation for in vitro fertilization |
ES2286008T3 (es) | 1999-02-24 | 2007-12-01 | Novo Nordisk A/S | Tratamiento de la infertilidad. |
KR20010093280A (ko) | 1999-02-24 | 2001-10-27 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 불임증 치료 |
AU1123301A (en) * | 1999-10-27 | 2001-05-08 | General Hospital Corporation, The | Methods and compositions for enhancing developmental potential of oocytes and zygotes |
WO2001036445A1 (en) | 1999-11-18 | 2001-05-25 | The Brigham And Women's Hospital, Inc. | Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
US6875854B1 (en) | 1999-11-18 | 2005-04-05 | The Brigham And Women's Hospital, Inc. | Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
US6544166B1 (en) | 1999-11-25 | 2003-04-08 | Groendahl Christian | Treatment of human infertility |
US6762053B2 (en) * | 2000-06-09 | 2004-07-13 | Vitrolife, Inc. | Mammalian gamete and embryo culture media and culture media supplements |
FR2812004B1 (fr) | 2000-07-24 | 2002-12-27 | Ccd Lab | Milieux de culture pour fecondation in vitro, ou pour la culture de follicules, cellules germinales males ou embryons |
US7226994B2 (en) | 2001-01-18 | 2007-06-05 | Cambridge University Technical Services Limited | Cell surface expressed marker of pluripotency |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2005002672A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
WO2005007687A1 (en) | 2003-07-09 | 2005-01-27 | Dana-Farber Cancer Institute, Inc | Compositions and methods for modulating ovarian follicular initiation |
US20050130302A1 (en) | 2003-09-29 | 2005-06-16 | Reprocell Inc. | Method and composition for regulating expansion of stem cells |
AU2004312072B2 (en) | 2003-12-29 | 2011-06-23 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
SI1765085T1 (sl) | 2004-05-17 | 2015-11-30 | The General Hospital Corporation | Sestavki, ki vsebujejo ženske zarodne matične celice in postopki njihove uporabe |
US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
WO2006001982A2 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ, インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
WO2006105440A2 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
US20090137681A1 (en) | 2005-04-08 | 2009-05-28 | David A Sinclair | Sirtuin Inhibiting Compounds |
US20080050347A1 (en) * | 2006-08-23 | 2008-02-28 | Ichim Thomas E | Stem cell therapy for cardiac valvular dysfunction |
WO2008026018A1 (en) * | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
US20120135091A1 (en) * | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
US8062222B2 (en) | 2007-06-13 | 2011-11-22 | Litron Laboratories, Ltd. | Method for measuring in vivo hematotoxicity with an emphasis on radiation exposure assessment |
US20090111764A1 (en) | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Mitochondrial selection |
NO331476B1 (no) * | 2007-12-21 | 2012-01-16 | Jaffar Ali Bin M Abdullah | Proteinfri gamete- og embryo-handtering samt dyrkningsmedieprodukter inneholdende metylcellulose |
US8415094B2 (en) * | 2007-12-21 | 2013-04-09 | Jaffar Ali bin M. Abdullah | Protein-free gamete and embryo handling and culture media products |
WO2009087568A2 (en) | 2008-01-10 | 2009-07-16 | Universidade De Coimbra | Compositions comprising antioxidant and mitoprotective flavonoids with neuroprotective properties |
EP2213288A1 (en) | 2009-01-30 | 2010-08-04 | Karl Welte | NAMPT and vitamin B3 for treating or preventing diseases |
US8527209B2 (en) | 2010-06-24 | 2013-09-03 | The Invention Science Fund I, Llc | Rejuvenation or preservation of germ cells |
US8338178B2 (en) | 2010-10-28 | 2012-12-25 | The Invention Science Fund I, Llc | Mitochondrial enhancement of cells |
JP2012105585A (ja) * | 2010-11-17 | 2012-06-07 | Nippon Ika Kikai Seisakusho:Kk | 人工受精用組成物 |
US8647869B2 (en) | 2011-04-14 | 2014-02-11 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
-
2012
- 2012-04-13 WO PCT/US2012/033672 patent/WO2013002880A1/en active Application Filing
- 2012-04-13 US US13/447,083 patent/US9845482B2/en active Active
- 2012-04-13 UA UAA201400826A patent/UA117448C2/uk unknown
- 2012-04-13 BR BR112013033797A patent/BR112013033797A2/pt active Search and Examination
- 2012-04-13 JP JP2014518556A patent/JP6284475B2/ja not_active Expired - Fee Related
- 2012-04-13 AU AU2012276038A patent/AU2012276038B2/en not_active Ceased
- 2012-04-13 CA CA2847292A patent/CA2847292A1/en not_active Abandoned
- 2012-04-13 EA EA201490050A patent/EA201490050A1/ru unknown
- 2012-04-13 CN CN201280040259.8A patent/CN103827293A/zh active Pending
- 2012-04-13 MX MX2014000201A patent/MX356815B/es active IP Right Grant
- 2012-04-13 EP EP18203134.4A patent/EP3495470A1/en not_active Withdrawn
- 2012-04-13 EP EP12804411.2A patent/EP2726601B1/en not_active Not-in-force
-
2013
- 2013-12-20 ZA ZA2013/09707A patent/ZA201309707B/en unknown
- 2013-12-26 IL IL230212A patent/IL230212B/en active IP Right Grant
-
2015
- 2015-02-26 US US14/632,754 patent/US20160024527A1/en not_active Abandoned
-
2017
- 2017-06-13 JP JP2017116146A patent/JP6496359B2/ja not_active Expired - Fee Related
- 2017-10-27 AU AU2017251852A patent/AU2017251852A1/en not_active Abandoned
- 2017-11-17 US US15/816,647 patent/US20180100166A1/en not_active Abandoned
-
2018
- 2018-03-14 IL IL258129A patent/IL258129A/en unknown
- 2018-07-13 US US16/034,446 patent/US20190002919A1/en not_active Abandoned
- 2018-10-29 JP JP2018202431A patent/JP2019030326A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013002880A4 (en) | 2013-02-21 |
ZA201309707B (en) | 2019-09-25 |
EP2726601B1 (en) | 2018-12-26 |
JP6496359B2 (ja) | 2019-04-03 |
CA2847292A1 (en) | 2013-01-03 |
US20190002919A1 (en) | 2019-01-03 |
US20160024527A1 (en) | 2016-01-28 |
IL230212B (en) | 2018-08-30 |
US20180100166A1 (en) | 2018-04-12 |
AU2012276038B2 (en) | 2017-08-31 |
MX356815B (es) | 2018-06-07 |
MX2014000201A (es) | 2014-06-11 |
EA201490050A1 (ru) | 2014-07-30 |
JP6284475B2 (ja) | 2018-02-28 |
BR112013033797A2 (pt) | 2017-02-14 |
AU2012276038A1 (en) | 2014-02-20 |
EP2726601A4 (en) | 2015-04-15 |
CN103827293A (zh) | 2014-05-28 |
JP2017206526A (ja) | 2017-11-24 |
EP2726601A1 (en) | 2014-05-07 |
IL258129A (en) | 2018-05-31 |
JP2019030326A (ja) | 2019-02-28 |
US20130059384A1 (en) | 2013-03-07 |
AU2017251852A1 (en) | 2017-11-16 |
US9845482B2 (en) | 2017-12-19 |
EP3495470A1 (en) | 2019-06-12 |
WO2013002880A1 (en) | 2013-01-03 |
JP2014520526A (ja) | 2014-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA117448C2 (uk) | Середовище клітинної культури для культивування ооцита | |
MX2014002670A (es) | Uso de acilsulfonamidas para mejorar el rendimiento de las plantas. | |
IN2014DN08862A (uk) | ||
MX368976B (es) | Composiciones y metodos para controlar la fusariosis. | |
MX2013004405A (es) | Sobreexpresion de miarn en plantas para control de parasitos. | |
MX345399B (es) | Metodo de cultivo de celulas animales. | |
BR112012027430A2 (pt) | processo de cultivo de células aprimorado | |
ZA201403678B (en) | Methods and systems for growing plants using silicate-based substrates,cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives ,and formulations,processes and systems for the same | |
IN2013DE02977A (uk) | ||
NZ706806A (en) | Compositions and methods for autologous germline mitochondrial energy transfer | |
AR094190A1 (es) | Transformacion de soja para la produccion de eventos transgenicos eficientes y de alta productividad | |
PH12014501212A1 (en) | Compositions comprising 20-carbon fatty acids and methods of making and using same | |
WO2011056017A3 (ko) | 모낭 줄기세포의 대량 증식 방법 | |
GB2453074A (en) | Differentiation of primate pluripotent cells to hepatocyte-lineage cells | |
MY160740A (en) | Method of producing lauric acid-containing oil or fat | |
WO2017049240A8 (en) | Selection of pluripotent cells for production of fertile xy female mice | |
MY191870A (en) | Production of fertile xy female animals from xy es cells | |
EP2581442A4 (en) | PROCESS FOR PRODUCING HEMATOPOIETIC STEM CELLS | |
EA201000901A1 (ru) | Способ культивирования микроорганизмов, относящихся к порядку thraustochytriales | |
NZ629709A (en) | Compounds and methods for improving plant performance | |
RS53186B (en) | TIONING PROCEDURE AND TIONING REAGENT | |
BR112012033087A2 (pt) | procedimento para a obtenção de ácidos graxos de interesse farmacológico e nutritivo | |
UY34149A (es) | Metodo para purificar lignina | |
IN2014CN01889A (uk) | ||
WO2011085095A3 (en) | Enhanced protein expression |